Benefit of Octreotide LAR in Patients with Neuroendocrine Midgut Tumors Who Previously Progressed on Placebo Therapy: Two Cases From the PROMID Study Abstract #486

Introduction: In the phase IIIb PROMID study, patients with advanced low-/intermediate-grade midgut neuroendocrine tumors (NET) received Octreotide LAR (O; 30 mg IM q28d) or placebo (P). Median time to tumor progression (TTP) was increased 8.3 mo in patients receiving O v. P (HR=0.34; 95% CI, 0.20-0.59; P<0.0001).
Aim(s): Here we report on outcomes in two placebo-treated patients from PROMID who received open-label O (30 mg IM q28d) after progression.
Materials and methods: Patient A was a woman aged 56 with a high hepatic tumor load at enrollment who progressed (liver) after five mo. Patient B was a woman aged 71 with multiple small hepatic lesions (hepatic tumor load <10%) at enrollment who progressed after six mo.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Anja Rinke
Authors: Rinke A

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result